AMD

A minimum of 5,000 patients with up to 5 years of follow-up will be included in the study, with patients from a variety of practice settings and clinician experiences in 28 countries and 500 sites

Dr. Jennifer Lim reveals new data on Angiopoietin-2 inhibition as a target for addressing nAMD and DME.

In conversation with Ophthalmology Times Europe, Anat Loewenstein, MD, illuminates the outcomes of using an AI-based fluid quantification for remote retina monitoring and analysis.

Carl D. Regillo, MD, FACS, FASRS, discussed recent data from the DAVIO 2 trial in his presentation at the virtual Angiogenesis, Exudation, and Degeneration 2024.

Dr. Carl Regillo provided an overview of topline results and a deep dive into subgroup analyses of DAVIO 2 trial data.

Early-onset drusen maculopathy (EODM), is part of the age-related macular degeneration (AMD) phenotype that occurs in individuals under 55 years of age.

EODM may be an ideal candidate for development of complement gene therapy due to the high-impact genetic variants.

SriniVas R. Sadda, MD, sat down with David Hutton of Ophthalmology Times to discuss his presentation about precursor lesions for development of atrophy and AMD from the Angiogenesis Exudation and Degeneration 2024 event.

Multimodal technology bridges the gap between advanced age-related macular degeneration (AMD) biomarkers and clinical features.

David Hutton of Ophthalmology Times talks with Jeffrey Cleland, PhD, President and CEO of Ashvattha Therapeutics, about the company's D-4517.2, a unique nanomedicine technology for the treatment of wet AMD and DME.

David Hutton of Ophthalmology Times talks with Adrienne Scott, MD, FASRS, about her part in a panel discussion detailing emerging therapies for AMD.

A new case-control study found that older people ages 70 and older living in South Korea’s urban areas were at a significantly higher risk for developing incident exudative age-related macular degeneration.

A new case-control study found that older people ages 70 and older living in South Korea’s urban areas were at a significantly higher risk for developing incident exudative age-related macular degeneration.

According to the company, ABBV-RGX-314 continues to be well tolerated in over 100 patients from three dose levels with no drug-related serious adverse events. The new data was presented at the Hawaiian Eye and Retina meeting in Maui, by John Pitcher, MD, and includes 6-month results from two additional dose level 3 cohorts.

Principle findings showed that aflibercept 8 mg demonstrated similar improvements in BCVA and CST when compared to the 2 mg dose of aflibercept.

Company presenting data from the Phase II AAVIATE trial of suprachoroidal ABBV-RGX-314 for the treatment of wet age-related macular degeneration January 16 at the Hawaiian Eye and Retina 2024 Meeting.

Because acetylcholinesterase inhibitors have anti-inflammatory effects, authors of the study wanted to determine if these drugs reduce the risk of AMD in patients with Alzheimer’s disease.

The data indicated that patients with Alzheimer’s disease who were treated with acetylcholinesterase inhibitors had a slightly lower hazard of developing AMD compared with untreated patients.

The European Union approval applies to aflibercept 8 mg for treatment of nAMD and DME.

In a letter to shareholders, Ricciardi provided updates on Cognition’s 2024 pipeline and expected advances for several diseases.

The company announced more advancements of its RASP modulator platform, including plans for ADX-629 and ADX-246.

The company announced more advancements of its RASP modulator platform, including plans for ADX-629 and ADX-246.

This study compared AVT06 with aflibercept (Eylea) in patients with neovascular AMD.

If granted, this device would be assigned an official classification as a Class II device with special controls.